BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

...sepsis-associated-acute kidney injury (see “AM-Pharma Raises €116M Series C” ). Zucara raises $21M A round Zucara Therapeutics Inc....
...dropped HK$2.35 to HK$28.95 in Hong Kong on Tuesday. Targets SSTR2 - Somatostatin receptor 2 BioCentury Staff Zucara Therapeutics Inc. AM-Pharma...
BioCentury | Nov 18, 2016
Emerging Company Profile

Suppressing somatostatin

...its lead therapy with a pharma partner after demonstrating clinical proof of concept. COMPANY PROFILE Zucara Therapeutics Inc....
...B.C. MaRS Innovation, Toronto, Ontario Tulane University, New Orleans, La. University of Toronto, Toronto, Ontario Zucara Therapeutics Inc....
...hypoglycemic diabetic rats.” Diabetes (2013) Virginia Li, Staff Writer Centre for Drug Research and Development MaRS Innovation University of Toronto Zucara Therapeutics Inc. Somatostatin...
BioCentury | Oct 24, 2016
Company News

Centre for Drug Research and Development, Zucara Therapeutics deal

...CDRD declined to disclose financial terms. Centre for Drug Research and Development , Vancouver, B.C. Zucara Therapeutics Inc....
BioCentury | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

...thereafter. For CDRD, the deal builds on a successful 1H16, which saw the spin-out of Zucara Therapeutics Inc....
...by Zymeworks Inc. Source: BCIQ: BioCentury Online Intelligence; CDRD website Date Company Description October 2016 Zucara Therapeutics Inc....
...Calif. University of Minnesota, Minneapolis, Minn. University of Sussex, Falmer, U.K. Wellcome Trust, London, U.K. Zucara Therapeutics Inc....
Items per page:
1 - 4 of 4
BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

...sepsis-associated-acute kidney injury (see “AM-Pharma Raises €116M Series C” ). Zucara raises $21M A round Zucara Therapeutics Inc....
...dropped HK$2.35 to HK$28.95 in Hong Kong on Tuesday. Targets SSTR2 - Somatostatin receptor 2 BioCentury Staff Zucara Therapeutics Inc. AM-Pharma...
BioCentury | Nov 18, 2016
Emerging Company Profile

Suppressing somatostatin

...its lead therapy with a pharma partner after demonstrating clinical proof of concept. COMPANY PROFILE Zucara Therapeutics Inc....
...B.C. MaRS Innovation, Toronto, Ontario Tulane University, New Orleans, La. University of Toronto, Toronto, Ontario Zucara Therapeutics Inc....
...hypoglycemic diabetic rats.” Diabetes (2013) Virginia Li, Staff Writer Centre for Drug Research and Development MaRS Innovation University of Toronto Zucara Therapeutics Inc. Somatostatin...
BioCentury | Oct 24, 2016
Company News

Centre for Drug Research and Development, Zucara Therapeutics deal

...CDRD declined to disclose financial terms. Centre for Drug Research and Development , Vancouver, B.C. Zucara Therapeutics Inc....
BioCentury | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

...thereafter. For CDRD, the deal builds on a successful 1H16, which saw the spin-out of Zucara Therapeutics Inc....
...by Zymeworks Inc. Source: BCIQ: BioCentury Online Intelligence; CDRD website Date Company Description October 2016 Zucara Therapeutics Inc....
...Calif. University of Minnesota, Minneapolis, Minn. University of Sussex, Falmer, U.K. Wellcome Trust, London, U.K. Zucara Therapeutics Inc....
Items per page:
1 - 4 of 4